Mobile

Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limit...

Update Il y a 4 ans
Reference: EUCTR2012-002057-38

Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitation

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate the non-inferiority of QVA149 110/50 μg qd compared to placebo in terms of overall SAE rate from initiation of study treatment through 30 days post last treatment.

Inclusion criteria

  • Chronic Obstructive Pulmonary Disease (COPD)

Links